Microbicides 2004 Microbicides 200428-31 March 2004, Hilton London MetropoleThe conference42 million men, women and children worldwide were living with HIV by the end of December 2002 (source: UNAIDS), including five million newly-infected during that year alone. Another 45 million people will become infected between 2002 and 2010, unless the current transmission rates can be vastly reduced. Of the 42 million, 29.4 million live in sub-Saharan Africa and 58% of them are women. Not only are women more susceptible to HIV infection, many are powerless to insist on the use of condoms or other methods of protecting themselves. In this context, and with the knowledge that an effective HIV vaccine is unlikely to be available for several years, the need for an effective topical microbicide grows ever more urgent. 2004 should prove to be a landmark year in the field of microbicide development as the first Phase III trials of novel products are due to start – the next step along the road to making a microbicide available to the millions worldwide in desperate need of protection.The aims of the Microbicides 2004 conference are to:Report novel or innovative work in the microbicides fieldProvide updates on recent microbicides research, divided into three tracks: basic science, clinical science, and behavioural science (including public health and the microbicide marketplace)Provide a forum for the discussion of new developments in microbicide research including ethical, clinical, behavioural and methodological issuesPresent opportunities for knowledge-sharing between microbicide researchers, public-health workers and advocacy organisations.There will be an opening ceremony on the evening of Sunday 28 March at which politicians, policy makers and the international media are expected. The conference will run for a full three days, each of which will contain:Scientific overviews and presentations with plenary sessions, invited lecturers and presentations of original researchWorkshops to review issues unique to microbicides such as trial design and outcome measures, and ethical issues in the clinical trials of microbicidesPoster sessions. Focus on LondonFollowing the successful Microbicides conferences in Washington in 2000 and Antwerp in 2002, March 2004 sees the focus move to London.The venue is the Hilton Metropole Hotel, two minutes by taxi from Paddington station and the Heathrow Express, with a journey time from the airport of 15 minutes. The hotel is in walking distance of Hyde Park and London’s main shopping streets, and close to Imperial College. Accommodation will be available at the venue and other hotels in the vicinity.London in March offers a variety of diversions for out-of-conference relaxation, including sight-seeing and shopping; the arts and the theatre; and pubs, clubs and restaurants to suit every taste. Conference staff will be on hand to help delegates plan their spare time.To book your place or find out more information, e-mail info@microbicides2004.org.uk or telephone the Event Office on +44 (0) 20 7720 4411
Oral: invited speaker Oral: Track A Oral: Track B Oral: Track C Poster: Track A Poster: Track B Poster: Track C Abstract only Authors

02662 POTENTIAL REMEDY’S FOR DELIVERY OF HIGH-EFFECTIVE MEMBRANE-ACTING ANTI-HIV MICROBICIDES

data not supplied

Annually several million persons get infected with HIV via sexual route. To protect those who do not use contraceptives, efficient preparations are necessary: microbicids of vaginal application. As a rule, preparations exhibiting efficient anti-HIV action in vitro cause irritation when applied locally on vaginal mucous membrane, which can cause a decrease in antiviral activity, perhaps due to involvement of ?D4+ cells. In the present work, we investigated routes for the creation of efficient pharmaceutical form of microbicid preparation based on conjugates of polymeric carboxylic acid with adamantane, norbornane, norbornene, and peptide imitators of HIV-1/2 coreceptors. In order to eliminate irritating action and increase microbicid activity, we included efficient membrane-acting anti-HIV compounds into the ??-dependent interpolymeric complex (IPC) which is stable into weakly acidic media and decomposes with the release of active anti-HIV preparation in neutral and/or alkaline media, with one of the following polymers: sodium alginate, polyvinylpyrrolidone (PVP), partly hydrolyzed chitosan, polyvinylimidazole, or included into the complex: PVP-polyacrylic acid. We propose to use carbopole, hyaluronic acid, sodium alginate, or chitosan (depending on the IPC used) as a gel-forming component for the final pharmaceutical form. The anti-HIV efficiency of some IPC proposed has been demonstrated experimentally in vitro, along with a decrease in local toxic action of preparation included in the IPC in vivo when applied on

Dr Tatyana Ryabicheva
State Research Center of Virology and Biotechnology ‘Vector’
(Telephone) 7-3832-366060 (Fax) 7-3832-366204 (E-mail) varaksin@vector-best.ru